A New ADHD Drug Hits Three Brain Chemicals Instead of Two — Heres What That Actually Means

A New ADHD Drug Hits Three Brain Chemicals Instead of Two — Heres What That Actually Means

Imagine youre texting a friend, and the moment you hit send, your phone automatically deletes the message before they can read it. Thats essentially what happens in the brain when neurotransmitters — the chemical messengers that carry signals between brain cells — get reabsorbed too quickly. For people with ADHD, this process can run a little too efficiently, leaving less dopamine and noradrenaline available to support attention, motivation, and self-control.

Now, a new medication called centanafadine, sold under the brand name Simtriyo, has entered the treatment landscape. Its a once-a-day tablet approved in the United States for adults and children aged six and older. But it isnt yet available in Australia. So what makes it different from the ADHD medications that have been around for decades?

The first of its kind to target three chemicals

Centanafadine belongs to a new class of ADHD medicines. Its the first to affect three brain chemicals: noradrenaline (called norepinephrine in the US), dopamine, and serotonin. Most existing ADHD drugs target only two — dopamine and noradrenaline.

Dopamine and noradrenaline are involved in attention, motivation, and self-control. Serotonin helps regulate mood, sleep, and appetite. By slowing down the reuptake process — the brains version of deleting a sent text — centanafadine leaves more of all three chemicals available for longer, helping brain cells communicate more effectively.

That three-chemical approach is what sets it apart. It may help reduce problems with attention, hyperactivity, and self-control, but it also raises an interesting question: could it do more than existing options?

Stimulant or not? The debate is real

Most ADHD medicines are stimulants — dexamfetamine, lisdexamfetamine, and methylphenidate are the well-known names. They mainly increase dopamine and noradrenaline activity. Centanafadine works similarly but adds serotonin to the mix.

Heres where it gets slightly confusing. The pharmaceutical company that developed the drug called it a non-stimulant back in 2017. But the US Food and Drug Administration (FDA) labels it a stimulant in the product information. So which is it? The short answer: it occupies a gray area. What matters more is that having another treatment option is genuinely useful, because not everyone responds to ADHD medicines in the same way.

Its not an antidepressant, even though it touches serotonin

Because centanafadine affects serotonin, some people might wonder if its an antidepressant. It isnt. Most commonly used antidepressants mainly affect serotonin, and some also affect noradrenaline. They generally dont increase dopamine activity enough to treat the core symptoms of ADHD. Some older antidepressants do affect dopamine, but they havent been extensively studied for ADHD.

Centanafadine affects reuptake of all three chemicals — dopamine, noradrenaline, and serotonin. Thats the key difference.

How it compares to Strattera

Strattera is the brand name for atomoxetine. It mainly increases noradrenaline availability in the brain, with much less effect on dopamine and serotonin. Because it has less impact on dopamine reward pathways, its not considered a stimulant. Centanafadine casts a wider net.

What the research actually shows

Centanafadine was tested in four large phase-3 clinical trials before US approval. These studies found that people taking it had improved ADHD symptoms, and the medicine was generally well tolerated. But theres a catch: the trials compared centanafadine with a placebo, not head-to-head with methylphenidate, dexamfetamine, or atomoxetine. So we cant yet say whether it works better than existing options — only that it works.

Only some results have been made publicly available. For most trials, researchers reported their own ratings of symptoms. We have less information about how participants themselves felt the medicine affected them.

One study in teenagers found ADHD symptoms improved within about a week of starting centanafadine. Side effects included reduced appetite, headache, nausea, and rash. Another study indirectly compared centanafadine trials with previous studies of lisdexamfetamine and atomoxetine. It suggested centanafadine may cause less insomnia, anxiety, dry mouth, and loss of appetite than lisdexamfetamine. But because this wasnt a direct comparison in the same trial, those results should be interpreted carefully.

The side effects to know about

The most common side effects reported with centanafadine include reduced appetite, insomnia, dry mouth, and headache. These can also occur with other ADHD medicines. The prescribing information also includes a warning about suicidal thoughts and behaviours — a warning that appears on other ADHD and depression medications too. Researchers and the manufacturer will continue monitoring the drug as more people use it.

Why Australians cant get it yet

Centanafadine hasnt been approved by Australias Therapeutic Goods Administration (TGA), nor listed on the Pharmaceutical Benefits Scheme (PBS). If it passes regulatory review, it may become available through normal treatment pathways. But TGA approval is a prerequisite for PBS subsidy consideration.

Could it help with anxiety or depression too?

Possibly, but we dont fully know yet. Because centanafadine affects serotonin alongside dopamine and noradrenaline, researchers are interested in whether it could help people who have ADHD plus anxiety or depression. Early research has shown some promising results, but the full findings of a study looking at ADHD and anxiety havent been published yet.

The practical takeaway

If you or someone you know is navigating ADHD treatment, centanafadine represents a genuinely new option — not a miracle cure, not a replacement for everything else, but another tool in the toolbox. The fact that it targets three brain chemicals instead of two is scientifically interesting, and it may eventually prove helpful for people who havent responded well to existing medications.

But the evidence so far comes with caveats: no direct comparisons with older drugs, limited patient-reported outcomes, and no availability outside the US. More research and real-world experience will clarify where it fits.

For now, the best move is to talk to a healthcare professional about whats available where you live — and to keep an eye on how this new class of ADHD medication evolves. The brain is complicated, and so is treating it. Having more options is rarely a bad thing.

Related Articles

The ADHD and Autism Diagnosis Shift: Why Todays Diagnosed Kids Look More Like Everyone Else

Zombieing: The Dating Trend That Makes Ghosting Look Like a Warm-Up

The ADHD Misdiagnosis Hiding in Your Childs Bedtime Routine

The Brains Blue Place Isnt a Foghorn — Its a Precision Postal Network, Scientists Discover

When Neurodivergent Becomes a Catch-All, Science Gets Lost in Translation

The Word Neurodivergent Is Everywhere. Science Says We Still Dont Know What It Means.